Evidence map›Paper›PMID 36151395›Full record

ArticleNature immunology2022

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.

Juan Dubrot, Peter P Du, Sarah Kate Lane-Reticker, Emily A Kessler, Audrey J Muscato, Arnav Mehta, Samuel S Freeman, Peter M Allen, Kira E Olander, Kyle M Ockerman and 23 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 207 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Reinvigorating COTL1Nature cell biology · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 2 institutions in 2 countries.

Juan Dubrot *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Peter P Du *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2652-0541
Sarah Kate Lane-RetickerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Emily A KesslerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Audrey J MuscatoBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2009-6313
Arnav MehtaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Samuel S FreemanBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8285-0057
Peter M AllenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kira E OlanderBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3356-7631
Kyle M OckermanBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Clara H WolfeBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Fabius WiesmannBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Nelson H KnudsenBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0384-1097
Hsiao-Wei TsaoBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Arvin Iracheta-VellveBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6635-3904
Emily M SchneiderBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5778-9119
Andrea N Rivera-RosarioBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Ian C KohnleBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Hans W PopeBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Austin AyerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Gargi MishraBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4063-6797
Margaret D ZimmerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3317-6569
Sarah Y KimBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Animesh MahapatraBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Hakimeh Ebrahimi-NikBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Dennie T FrederickCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3355-5267
Genevieve M BolandCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
W Nicholas HainingBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7871-3762
David E RootBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5122-861X
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3707-9889
Nir HacohenBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2349-2656
Kathleen B YatesBroad Institute of MIT and Harvard, Cambridge, MA, USA. yates@broadinstitute.org.ORCID http://orcid.org/0000-0002-7383-5573
Robert T MangusoBroad Institute of MIT and Harvard, Cambridge, MA, USA. rmanguso@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-1336-413X
Broad Institute · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune system can eliminate tumors, but checkpoints enable immune escape. Here, we identify immune evasion mechanisms using genome-scale in vivo CRISPR screens across cancer models treated with immune checkpoint blockade (ICB). We identify immune evasion genes and important immune inhibitory checkpoints conserved across cancers, including the non-classical major histocompatibility complex class I (MHC class I) molecule Qa-1

Indexed as

CD8-Positive T-LymphocytesNeoplasmsClustered Regularly Interspaced Short Palindromic RepeatsHistocompatibility Antigens Class IHumansImmune Checkpoint InhibitorsImmune EvasionInterferon-gammaNK Cell Lectin-Like Receptor Subfamily CHistocompatibility Antigens Class IImmune Checkpoint InhibitorsInterferon-gammaNK Cell Lectin-Like Receptor Subfamily C

Identifiers

PMID36151395
OpenAlexW4297088172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.